Holen Sie sich die Stockscreener-App
78.00
3.31%
-2.67
Handel nachbörslich:
78.00
Schlusskurs vom Vortag:
$80.67
Offen:
$80
24-Stunden-Volumen:
40,274
Relative Volume:
0.08
Marktkapitalisierung:
$83.49M
Einnahmen:
$7.10M
Nettoeinkommen (Verlust:
$-39.43M
KGV:
-82.98
EPS:
-0.94
Netto-Cashflow:
$-46.50M
1W Leistung:
-18.02%
1M Leistung:
-26.65%
6M Leistung:
-86.69%
1J Leistung:
-90.34%
1-Tages-Spanne:
$75.21
$82.40
1-Wochen-Bereich:
$75.21
$95.05
52-Wochen-Spanne:
$7.26
$543.38
Spruce Biosciences Inc Stock (SPRB) Company Profile
Firmenname
Spruce Biosciences Inc
Sektor
Branche
Telefon
(415) 655-4168
Adresse
611 GATEWAY BOULEVARD, SUITE 740, SOUTH SAN FRANCISCO
Vergleichen Sie SPRB mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SPRB
Spruce Biosciences Inc
|
78.00 | 86.35M | 7.10M | -39.43M | -46.50M | -0.94 |
|
VRTX
Vertex Pharmaceuticals Inc
|
454.96 | 115.62B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
746.36 | 79.10B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
851.42 | 52.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
391.17 | 51.72B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
200.67 | 42.00B | 447.02M | -1.18B | -906.14M | -6.1812 |
Spruce Biosciences Inc Stock (SPRB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-03 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2025-10-28 | Hochstufung | Citizens JMP | Mkt Perform → Mkt Outperform |
| 2024-12-11 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2024-12-11 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2024-03-14 | Herabstufung | Guggenheim | Buy → Neutral |
| 2024-03-14 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2024-03-14 | Herabstufung | Ladenburg Thalmann | Buy → Neutral |
| 2024-03-14 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-03-14 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-02-21 | Eingeleitet | Guggenheim | Buy |
| 2021-12-17 | Eingeleitet | Oppenheimer | Outperform |
| 2021-12-10 | Eingeleitet | The Benchmark Company | Speculative Buy |
| 2021-11-16 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2021-07-19 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2020-11-03 | Eingeleitet | Cowen | Outperform |
| 2020-11-03 | Eingeleitet | Credit Suisse | Outperform |
| 2020-11-03 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2020-11-03 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Spruce Biosciences Inc Aktie (SPRB) Neueste Nachrichten
Spruce Biosciences Appoints Proven Pharmaceutical Commercial Leader Keli Walbert to Board of Directo - PharmiWeb.com
Spruce Biosciences appoints Keli Walbert to board of directors - marketscreener.com
Spruce Biosciences Appoints Keli Walbert To Board Of Directors - TradingView — Track All Markets
Spruce Biosciences Appoints Keli Walbert as Director - TipRanks
Spruce Biosciences (NASDAQ: SPRB) names rare-disease veteran Keli Walbert to board - Stock Titan
Wall Street Zen Upgrades Spruce Biosciences (NASDAQ:SPRB) to Hold - MarketBeat
Spruce Biosciences (SPRB) Price Target Increased by 55.76% to 213.69 - Nasdaq
Spruce Biosciences (NASDAQ:SPRB) Raised to Strong-Buy at Leerink Partnrs - MarketBeat
Spruce Biosciences (NASDAQ:SPRB) Upgraded to "Outperform" at Leerink Partners - MarketBeat
Leerink Partners Upgrades Spruce Biosciences (SPRB) - Nasdaq
Spruce Biosciences Shares Rise After Upgrade From Leerink - marketscreener.com
SPRB: Leerink Partners Upgrades to Outperform with $160 Target | - GuruFocus
Leerink Partners upgrades Spruce Biosciences stock to Outperform By Investing.com - Investing.com Canada
Leerink Partners upgrades Spruce Biosciences stock to Outperform - Investing.com
After-Hours Spotlight: Jasper, NRx, Unicycive, Spruce, Evaxion, Solana, Protara Gain Post-Close - Nasdaq
Spruce Biosciences (SPRB) Price Target Increased by 2,045.14% to 137.19 - Nasdaq
Spruce Biosciences (NASDAQ:SPRB) Upgraded to "Sell" at Wall Street Zen - MarketBeat
Is Spruce Biosciences Stock Built to Withstand More Downside? - Trefis
Citizens Jmp Forecasts Strong Price Appreciation for Spruce Biosciences (NASDAQ:SPRB) Stock - MarketBeat
Citizens raises Spruce Biosciences stock price target to $259 on MPS IIIB therapy - Investing.com Australia
Citizens raises Spruce Biosciences stock price target to $259 on MPS IIIB therapy By Investing.com - Investing.com South Africa
Citizens Maintains Spruce Biosciences (SPRB) Market Outperform Recommendation - Nasdaq
SPRB: Citizens Raises Price Target for Spruce Biosciences | SPRB Stock News - GuruFocus
Spruce Biosciences Reports Q3 2025 Financial Results - TipRanks
Spruce Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Updates - BioSpace
SPRB Announces Key Financing Milestones and Regulatory Achieveme - GuruFocus
Spruce Biosciences Q3 net loss narrows - MarketScreener
Spruce Biosciences Inc expected to post a loss of $13.93 a shareEarnings Preview - TradingView
Spruce Biosciences (SPRB) Expected to Announce Earnings on Monday - MarketBeat
One new option listing and two option delistings on September 5th - MSN
Small Cap Stocks To Follow TodayOctober 6th - MarketBeat
Biotech And Tech Stocks Rally On Breakthrough News And Partnerships - Finimize
Spruce Biosciences (SPRB) Price Target Decreased by 37.30% to 6.40 - MSN
[S-3] SPRUCE BIOSCIENCES, INC. Shelf Registration Statement | SPRB SEC FilingForm S-3 - Stock Titan
Spruce Biosciences, Inc. (NASDAQ:SPRB) Given Average Rating of "Hold" by Brokerages - MarketBeat
Spruce Biosciences (NASDAQ:SPRB) Upgraded to "Outperform" at Citizens Jmp - MarketBeat
Spruce Biosciences Stock Rallied 1184%Have You Assessed the Risk - Trefis
JMP Securities Upgrades Spruce Biosciences (SPRB) - Nasdaq
Cash per share of Spruce Biosciences, Inc. – NASDAQ:SPRB - TradingView
SPRB: JMP Securities Upgrades Spruce Biosciences to Market Outpe - GuruFocus
Spruce Biosciences Raised to Market Outperform From Market Perform by JMP Securities - 富途牛牛
Spruce Biosciences stock upgraded by Citizens on promising MPS IIIB therapy - Investing.com Nigeria
Spruce Biosciences Stock Dropped 16%Have You Assessed the Risk - Trefis
Spruce Biosciences (NASDAQ:SPRB) Stock Rating Lowered by Zacks Research - MarketBeat
What is Leerink Partnrs' Forecast for SPRB FY2025 Earnings? - MarketBeat
Levi & Korsinsky Reminds Spruce Biosciences Investors of the Ongoing Investigation into Potential Violations of Securities LawsSPRB - ACCESS Newswire
Spruce Biosciences Announces $50 Million Private Placement Financing - Global Legal Chronicle
Spruce Biosciences CFO vests 2,053 RSUs; owns 6,066 shares - Stock Titan
SPRB insider filing: CEO nets 3,245 shares after RSU vest - Stock Titan
The science behind the therapy that catapulted a biopharma’s stock 1,400% and counting - Healthcare Brew
Leerink Partners Maintains Spruce Biosciences (SPRB) Market Perform Recommendation - Nasdaq
Finanzdaten der Spruce Biosciences Inc-Aktie (SPRB)
Umsatz
Nettogewinn
Free Cashflow
ENV
Spruce Biosciences Inc-Aktie (SPRB) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Gharib Samir M. | PRESIDENT AND CFO |
Dec 10 '25 |
Option Exercise |
0.00 |
514 |
0 |
6,580 |
| Szwarcberg Javier B. | CHIEF EXECUTIVE OFFICER |
Dec 11 '25 |
Option Exercise |
0.00 |
4,950 |
0 |
15,192 |
| Szwarcberg Javier B. | CHIEF EXECUTIVE OFFICER |
Dec 10 '25 |
Option Exercise |
0.00 |
1,196 |
0 |
10,670 |
| Gharib Samir M. | PRESIDENT AND CFO |
Oct 20 '25 |
Option Exercise |
0.00 |
2,053 |
0 |
6,727 |
| Szwarcberg Javier B. | CHIEF EXECUTIVE OFFICER |
Oct 20 '25 |
Option Exercise |
0.00 |
4,784 |
0 |
11,013 |
| Parkman Healthcare Partners LL | 10% Owner |
Oct 06 '25 |
Buy |
17.91 |
256 |
4,585 |
1,307 |
| Parkman Healthcare Partners LL | 10% Owner |
Oct 06 '25 |
Sale |
19.14 |
257 |
4,920 |
1,050 |
| Parkman Healthcare Partners LL | 10% Owner |
Oct 06 '25 |
Buy |
17.91 |
256 |
4,585 |
1,307 |
| Parkman Healthcare Partners LL | 10% Owner |
Oct 06 '25 |
Sale |
19.14 |
257 |
4,920 |
1,050 |
0.42%
0.32%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):